Drug Profile
CTT 1401
Alternative Names: 177Lutetium CTT1401; [177Lu]CTT1401; CTT1401Latest Information Update: 13 Sep 2023
Price :
$50
*
At a glance
- Originator Cancer Targeted Technology
- Class Antineoplastics; Radiopharmaceuticals
- Mechanism of Action DNA modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Prostate cancer
Most Recent Events
- 13 Sep 2023 Discontinued - Preclinical for Prostate cancer in USA (Parenteral) (Cancer Targeted Technology pipeline, September 2023)
- 28 Oct 2019 No recent reports of development identified for preclinical development in Prostate-cancer in USA (Parenteral, Injection)